BRPI0413679A - formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia - Google Patents

formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia

Info

Publication number
BRPI0413679A
BRPI0413679A BRPI0413679-9A BRPI0413679A BRPI0413679A BR PI0413679 A BRPI0413679 A BR PI0413679A BR PI0413679 A BRPI0413679 A BR PI0413679A BR PI0413679 A BRPI0413679 A BR PI0413679A
Authority
BR
Brazil
Prior art keywords
inhibitor
treatment
formulations
neoplasia
modulating agent
Prior art date
Application number
BRPI0413679-9A
Other languages
English (en)
Inventor
Jaime L Masferrer
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0413679A publication Critical patent/BRPI0413679A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"FORMULAçõES DE UM INIBIDOR SELETIVO DA CICLOOXIGENASE-2 E DE UM AGENTE DE MODULAçãO DA SEROTONINA PARA O TRATAMENTO DA NEOPLASIA". A presente invenção proporciona formulações e métodos para o tratamento de neoplasia em um indivíduo. Mais particularmente, a invenção proporciona uma terapêutica de associação para o tratamento de uma neoplasia compreendendo a administração a um indivíduo de um agente de modulação da serotonina associado a um inibidor seletivo da ciclooxigenase-2.
BRPI0413679-9A 2003-08-22 2004-08-20 formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia BRPI0413679A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49720203P 2003-08-22 2003-08-22
PCT/US2004/027326 WO2005018569A2 (en) 2003-08-22 2004-08-20 Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia

Publications (1)

Publication Number Publication Date
BRPI0413679A true BRPI0413679A (pt) 2006-10-24

Family

ID=34216096

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0413679-9A BRPI0413679A (pt) 2003-08-22 2004-08-20 formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia

Country Status (7)

Country Link
US (1) US20050085477A1 (pt)
EP (1) EP1660079A2 (pt)
JP (1) JP2007503396A (pt)
BR (1) BRPI0413679A (pt)
CA (1) CA2536340A1 (pt)
MX (1) MXPA06002112A (pt)
WO (1) WO2005018569A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175606B2 (en) 2002-05-24 2007-02-13 Baxter International Inc. Disposable medical fluid unit having rigid frame
US7153286B2 (en) 2002-05-24 2006-12-26 Baxter International Inc. Automated dialysis system
FR2888506A1 (fr) * 2005-07-12 2007-01-19 Cerenis Sa Utilisation de la 4-(3,4-dichloro-phenyl)-1,2,3,4- tetrahydro-naphtalen-1-ylamine pour le traitement du cancer
FR2909283A1 (fr) * 2006-11-30 2008-06-06 Cerep Sa Produit de combinaison contenant de la n-desmethylsertraline, ou un de ses sels, et un agent antineoplasique pour le traitement du cancer
JP5647519B2 (ja) 2007-09-13 2014-12-24 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化カテコールおよびベンゾ［ｄ］［１，３］ジオキソールおよびその誘導体の合成
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
US9073851B2 (en) 2011-10-28 2015-07-07 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5618846A (en) * 1990-12-17 1997-04-08 University Of Manitoba Treatment method for cancer
US5436246A (en) * 1992-09-17 1995-07-25 Merrell Dow Pharmaceuticals Inc. Serotonin receptor agents
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
GEP20032998B (en) * 1996-04-12 2003-06-25 Searle & Co Substituted Benzenesulfonamide Derivatives as Prodrugs of Cox-2 Inhibitors
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy

Also Published As

Publication number Publication date
US20050085477A1 (en) 2005-04-21
WO2005018569A2 (en) 2005-03-03
WO2005018569A3 (en) 2005-11-03
MXPA06002112A (es) 2006-05-17
JP2007503396A (ja) 2007-02-22
EP1660079A2 (en) 2006-05-31
CA2536340A1 (en) 2005-03-03

Similar Documents

Publication Publication Date Title
BR0313282A (pt) Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
BR9916518A (pt) Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
EP1670450A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING LEVODOPA AND CARBIDOPA
BR0304648A (pt) Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia
NZ599464A (en) Combination therapies using hdac inhibitors
TW200612862A (en) Treatment of skin with light and a benefit agent to mitigate acne
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
BR112023002458A2 (pt) Métodos de tratamento da gota
DE60121303D1 (de) Mittel, wie nikotinamide oder cadpr zur behandlung von hautkrankheiten
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2004093813A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
PT1631275E (pt) Tratamento e prevenção da cicatrização excessiva com 4-hidroxi-tamoxifeno
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
WO2004093816A3 (en) Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
WO2005018569A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a serotonin modulating agent for the treatment of neoplasia
DE60020556D1 (de) Ionenkanal modulierende mittel
BR0317021A (pt) Imitadores da superóxido dismutase para o tratamento de distúrbios e de doenças oculares
WO2005018541A3 (en) Cox-2 inhibitor and serotonin modulator for treating cns damage
BR0316475A (pt) Combinação sinergìstica que compreende roflumilast e (r,r)-formoterol

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]